Scaling a viral vector process from benchtop to clinical supply isn't a bigger version of monoclonal antibody (mAb) manufacturing, but an entirely different analytical challenge. Cell and gene therapy ...

Although all this growth is encouraging, it is also straining global manufacturing capacities. Biopharma manufacturers are under pressure to find innovative platform technologies to bring products to ...

BUILDING pharmaceutical quality directly into the supply chain via rigorous upstream validation, rather than simply relying ...

Officials at Cytiva and Culture Biosciences say the companies are collaborating to advance innovation in upstream bioprocessing by providing customers greater access to predictive and robust scale-up ...